Pancreatic carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
STB2 is highly expressed in MKN28, MKN74 (gastric cancer), BxPC-3, PSN-1, and Hs766T (pancreatic cancer) cells.
|
12060845 |
2002 |
Malignant neoplasm of pancreas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
STB2 is highly expressed in MKN28, MKN74 (gastric cancer), BxPC-3, PSN-1, and Hs766T (pancreatic cancer) cells.
|
12060845 |
2002 |
Stomach Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
STB2 is highly expressed in MKN28, MKN74 (gastric cancer), BxPC-3, PSN-1, and Hs766T (pancreatic cancer) cells.
|
12060845 |
2002 |
Sacral agenesis
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
Sacral agenesis
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Sacral agenesis
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
Neural Tube Defects
|
0.600 |
Biomarker
|
group |
BEFREE |
These findings implicate VANGL1 as a risk factor in human neural-tube defects.
|
17409324 |
2007 |
Neural Tube Defects
|
0.600 |
Biomarker
|
group |
GENOMICS_ENGLAND |
|
|
|
Neural Tube Defects
|
0.600 |
Biomarker
|
group |
BEFREE |
This study provides further evidence supporting the role of VANGL1 as a risk factor in the development of spinal NTDs.
|
19319979 |
2009 |
Neural Tube Defects
|
0.600 |
Biomarker
|
group |
CTD_human |
These findings implicate VANGL1 as a risk factor in human neural-tube defects.
|
17409324 |
2007 |
Neural Tube Defects
|
0.600 |
Biomarker
|
group |
BEFREE |
In 48 children with a neural tube defect and 62 controls from a Dutch case-control study and 34 children with a neural tube defect and 78 controls from a Texan case-control study, we measured the DNA-methylation levels of imprinted candidate genes (IGF2-DMR, H19, KCNQ1OT1) and non-imprinted genes (the LEKR/CCNL gene region associated with birth weight, and MTHFR and VANGL1 associated with NTD).
|
24223810 |
2013 |
Neural Tube Defects
|
0.600 |
Biomarker
|
group |
BEFREE |
Scribble1 plays an important role in the pathogenesis of neural tube defects through its mediating effect of Par-3 and Vangl1/2 localization.
|
28369449 |
2017 |
Neural Tube Defects
|
0.600 |
Biomarker
|
group |
CTD_human |
This study provides further evidence supporting the role of VANGL1 as a risk factor in the development of spinal NTDs.
|
19319979 |
2009 |
Caudal Regression Syndrome
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Sacral defect and anterior sacral meningocele
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Sacral defect and anterior sacral meningocele
|
0.600 |
Biomarker
|
disease |
CTD_human |
|
|
|
NEURAL TUBE DEFECTS, SUSCEPTIBILITY TO
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Mutations in VANGL1 associated with neural-tube defects.
|
17409324 |
2007 |
Caudal Dysgenesis Syndrome
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
|
|
|
Caudal Dysgenesis Syndrome
|
0.500 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
|
|
|
Craniorachischisis
|
0.310 |
Biomarker
|
disease |
CTD_human |
Mutations in VANGL1 associated with neural-tube defects.
|
17409324 |
2007 |
Craniorachischisis
|
0.310 |
Biomarker
|
disease |
CTD_human |
Novel mutations in VANGL1 in neural tube defects.
|
19319979 |
2009 |
Diastematomyelia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Novel mutations in VANGL1 in neural tube defects.
|
19319979 |
2009 |
Diastematomyelia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mutations in VANGL1 associated with neural-tube defects.
|
17409324 |
2007 |
Neurenteric Cyst
|
0.300 |
Biomarker
|
disease |
CTD_human |
Novel mutations in VANGL1 in neural tube defects.
|
19319979 |
2009 |
Neurenteric Cyst
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mutations in VANGL1 associated with neural-tube defects.
|
17409324 |
2007 |